<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The mechanisms underlying the <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mp ids='MP_0001858'>intestinal inflammation</z:mp> that is a hallmark of <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel diseases</z:e> (IBD) are complex </plain></SENT>
<SENT sid="1" pm="."><plain>Components of the pathological response include the adaptive and innate immune systems, as well as the intestinal epithelium and endothelium </plain></SENT>
<SENT sid="2" pm="."><plain>Advances in the understanding of the roles of each of these components have resulted in the development of multiple biological agents that <z:hpo ids='HP_0000001'>all</z:hpo> represent an alternative to the use of current therapies in patients with refractory <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> or <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>This study systematically reviews the mechanisms of action, efficacy and safety of new and emerging therapies that are currently in clinical trials and discusses future directions in the treatment of IBD </plain></SENT>
</text></document>